XBiotech (XBIT) and Athenex (ATNX) Head to Head Review

XBiotech (NASDAQ: XBIT) and Athenex (NASDAQ:ATNX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for XBiotech and Athenex, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech 0 1 1 0 2.50
Athenex 0 1 5 0 2.83

XBiotech currently has a consensus target price of $13.00, suggesting a potential upside of 171.97%. Athenex has a consensus target price of $28.17, suggesting a potential upside of 65.88%. Given XBiotech’s higher possible upside, equities research analysts clearly believe XBiotech is more favorable than Athenex.


This table compares XBiotech and Athenex’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XBiotech N/A -60.07% -55.80%
Athenex N/A N/A N/A

Institutional and Insider Ownership

9.3% of XBiotech shares are held by institutional investors. Comparatively, 6.0% of Athenex shares are held by institutional investors. 35.7% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares XBiotech and Athenex’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XBiotech N/A N/A -$52.76 million ($1.63) -2.93
Athenex N/A N/A N/A N/A N/A


Athenex beats XBiotech on 4 of the 7 factors compared between the two stocks.

XBiotech Company Profile

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Athenex Company Profile

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company’s Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply